Halozyme(HALO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue of $231 million; Net Income of$93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of$0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12$125 million ® ® Partner Approvals for Ocrevus SC in Europe and the UK and VYVGART Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 -$1,015 million, Representing YOY Growth of 13% - 22 ...